GTS400 Stent Implantation in Conjunction With Cataract Surgery in Subjects With Open-angle Glaucoma
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the safety and efficacy of the GTS400 trabecular micro-bypass stent in reducing intraocular pressure (IOP) in subjects with open-angle glaucoma or ocular hypertension and co-existing cataract.
| Condition | Intervention | Phase |
|---|---|---|
|
Glaucoma |
Device: iStent Inject (GTS400) Procedure: Cataract Surgery |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Prospective, Randomized, Controlled, Parallel Groupos, Multicenter Clinical Investigation of the Glaukos Trabecular Micro-bypass Stent Model GTS400 in Conjunction With Cataract Surgery |
- Proportion of subjects with 12 month diurnalIOP </= 21 mmHg without use of ocular hypotensive medications for >/= 4 weeks prior to 12 month visit. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 500 |
| Study Start Date: | January 2010 |
| Estimated Study Completion Date: | August 2013 |
| Estimated Primary Completion Date: | August 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Cataract Surgery Only |
Procedure: Cataract Surgery
Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery only.
Other Name: Cataract surgery
|
|
Experimental: Treatment with Cataract Surgery & Stents
Ab interno trabecular micro-bypass stent surgery
|
Device: iStent Inject (GTS400)
Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery with subsequent implantation of GTS400 stents.
Other Name: Cataract surgery, stent implantation
|
Detailed Description:
Glaucoma is a collection of disorders characterized by progressive loss of visual field due to optic nerve damage. It is a leading cause of blindness in the United States, affecting 1-2% of individuals aged 60 and over. Management of glaucoma requires chronic, life-long treatment with a spectrum of therapeutic options including medications, laser treatment and surgical implants. The common goal among the various therapies is to lower intraocular pressure to target levels in order to prevent loss of visual fields from excessive pressure on the optic nerve.
Eligibility| Ages Eligible for Study: | 18 Years to 90 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosed with open-angle glaucoma in the study eye
- Subject must be on 1 to 3 glaucoma medications
- Subject able and willing to attend follow up visits for two years postop
- Subject able and willing to sign informed consent
Exclusion Criteria:
- Pseudoexfoliative and pigmentary glaucoma
- Prior glaucoma surgery of any type
Contacts and Locations
Show 22 Study Locations| Study Director: | Jeff Wells, PharmD, MBA | Glaukos Corporation |
| Study Chair: | Jay Katz, MD | Wills Eye Institute; Thomas Jefferson University |
More Information
No publications provided
| Responsible Party: | Glaukos Corporation |
| ClinicalTrials.gov Identifier: | NCT01052558 History of Changes |
| Other Study ID Numbers: | GC-006 |
| Study First Received: | January 13, 2010 |
| Last Updated: | September 4, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Glaukos Corporation:
|
Open angle Glaucoma Cataract Surgery Intraocular Pressure |
Additional relevant MeSH terms:
|
Glaucoma Glaucoma, Open-Angle Cataract |
Ocular Hypertension Eye Diseases Lens Diseases |
ClinicalTrials.gov processed this record on May 16, 2013